Hood River Capital Management’s Viking Therapeutics VKTX Stock Holding History

Hood River Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-51,400	Closed	-$1.24M	–	174
2025 Q1	$1.24M	Buy	51,400 +7,870	+18%	+$249K	0.02%	136
2024 Q4	$1.75M	Sell	43,530 -772,148	-95%	-$44M	0.03%	140
2024 Q3	$51.6M	Buy	815,678 +101,100	+14%	+$5.93M	0.83%	51
2024 Q2	$37.9M	Buy	714,578 +42,650	+6%	+$2.8M	0.78%	49
2024 Q1	$55.1M	Buy	+671,928	New	+$29.9M	1.23%	26

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Hood River Capital Management's VKTX Position: Q2 2025 in Review

Hood River Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 51,400 shares — an estimated $1.24M sold.

Hood River Capital Management first reported a position in VKTX in Q1 2024 and held it in 5 quarters. The position peaked at $55.1M in Q1 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Hood River Capital Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Hood River Capital Management sold 51,400 Viking Therapeutics shares in Q2 2025, an estimated $1.24M.
Hood River Capital Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 5 quarters.
Hood River Capital Management's Viking Therapeutics position peaked at $55.1M in Q1 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Hood River Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.